- Condition Centers
The FDA recently approved ranolazine extended-release tablets (Ranexa) for the treatment of angina, making it the first new pharmaceutical option for the treatment of angina in >20 years. According to a statement from the manufacturer, CV Therapeutics Inc, ranolazine prolongs the QT interval and therefore should be used in patients who have not achieved an adequate response with other antianginal drugs. Ranolazine should be used in combination with amlodipine, betablockers, or nitrates. The effect on angina rate or exercise tolerance appeared to be smaller in women than in men. CV Therapeutics expects to have Ranexa available to pharmacies later this spring.
Ms. Farley is a freelance medical writer based in Wakefield, RI.